Phase III open label First Line Therapy study of MEDI 4736 (Durvalumab) with or without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) - MYSTIC

Exclusion Criteria

• Patients should not enter the study if any of the following exclusion criteria are fulfilled:
• 1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
• 2. Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
• 3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
• 4. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn’s disease]